Pepaxto
FDA Withdrawals Approval of Pepaxto for Multiple Myeloma
The FDA has announced its final decision to withdraw approval of melphalan flufenamide, which was approved for use ...
FEBRUARY 26, 2024
FDA Approves Pepaxto for Triple-Refractory Multiple Myeloma
The FDA granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with ...
MARCH 5, 2021
Load more